Neuroinflammation
Human evidence and active trials are visible in this field
5 human-evidence records · 3 active trials · 63 visible funding records · 7,677 universities
Australian Patent Application
Alternative LAT1 Carrier Architectures CNS-Selective Hydroxychloroquine for Longevity and Neuroinflammation and Revival of Failed CNS Drug Candidates via Meta-Phenylalanine Prodrug Platform
Source-linked patent metadata for Alternative LAT1 Carrier Architectures CNS-Selective Hydroxychloroquine for Longevity and Neuroinflammation and Revival of Failed CNS Drug Candidates via Meta-Phenylalanine Prodrug Platform, including priority, record stage and longevity-topic connections.
Australian application snapshot
Patent application record
This privacy-minimal view describes one official Australian patent application record. It is not presented as a complete worldwide patent family.
- Application number
- AU2026902307
- Earliest priority
- March 18, 2026
- Application date
- March 18, 2026
- Source record
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Why names are absent
This feed intentionally excludes party names and contact details to minimise personal data. Open the official record when a name is consequential.
Topics connected by metadata
Neuroinflammation82% metadata match
How the patent office classifies this invention
No patent classification is available in the retained record.
Verify in the original patent source →